Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report

被引:7
作者
Yuki, Hideo [1 ]
Kamai, Takao [1 ]
Kubota, Keiichi [2 ]
Abe, Hideyuki [1 ]
Nishihara, Daisaku [1 ]
Mizuno, Tomoya [1 ]
Masuda, Akinori [1 ]
Betsunoh, Hironori [1 ]
Yashi, Masahiro [1 ]
Fukabori, Yoshitatsu [1 ]
Yoshida, Ken-Ichiro [1 ]
机构
[1] Dokkyo Med Univ, Dept Urol, Mibu, Tochigi 3210293, Japan
[2] Dokkyo Med Univ, Dept Surg Gastroenterol, Mibu, Tochigi 3210293, Japan
关键词
renal cell carcinoma; sarcomatoid differentiation; axitinib; tyrosine kinase inhibitors; phosphorylated Akt; TARGETED THERAPY; INTERFERON-ALPHA; PHASE-3; TRIAL; SORAFENIB;
D O I
10.2147/OTT.S58089
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Renal cell carcinoma (RCC) with sarcomatoid differentiation is invasive, refractory to treatment, and has a higher mortality. Therefore, systemic therapy is still challenging, and the curative resection of localized or locally advanced RCC with sarcomatoid differentiation is very important. Axitinib is a potent and selective second-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor with improved safety and tolerability. Axitinib is generally recommended as second-line therapy for advanced RCC because the phase III axitinib versus sorafenib in advanced RCC (AXIS) trial demonstrated that it achieved longer progression-free survival than sorafenib in patients with metastatic RCC after failure of an approved first-line regimen. Methods: We present a 73-year-old man who had a large (13 cm in diameter) right RCC with sarcomatoid differentiation that directly invaded the duodenum and inferior vena cava. The patient presented with gastrointestinal bleeding, was unable to eat solid food, and had become emaciated. Thus, his classification was poor risk with anemia, hypercalcemia, and poor - performance status, according to the Memorial Sloan-Kettering Cancer Center criteria. He seemed unlikely to survive if radical nephrectomy, cavotomy with thrombectomy, and pancreatoduodenectomy were performed. To reduce the tumor burden and potential operative complications, we administered axitinib as first-line neoadjuvant therapy. Results: Six weeks of treatment reduced the tumor burden without causing severe toxicities. Subsequently, radical right nephrectomy, cavotomy with thrombectomy, and pancreatoduodenectomy were performed successfully. The pathological treatment effect of axitinib was grade 2 (two-thirds necrosis). The resected tumor showed a heterogeneous reaction for phosphorylated Akt (Ser-473) by Western blotting and immunohistochemistry, indicating that parts of the tumor were sensitive to axitinib and other parts were not. Conclusion: Axitinib might be promising as preoperative or neoadjuvant therapy for locally advanced RCC (>cT3b or >cT(any)N1).
引用
收藏
页码:289 / 295
页数:7
相关论文
共 17 条
[1]   Recent advances in the treatment of metastatic renal cell carcinoma [J].
Abe, Hideyuki ;
Kamai, Takao .
INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (10) :944-955
[2]   Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis [J].
Flanigan, RC ;
Mickisch, G ;
Sylvester, R ;
Tangen, C ;
Van Poppel, H ;
Crawford, ED .
JOURNAL OF UROLOGY, 2004, 171 (03) :1071-1076
[3]   Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma [J].
Furuya, Nobutaka ;
Kamai, Takao ;
Shirataki, Hiromichi ;
Yanai, Yoshiaki ;
Fukuda, Takehiko ;
Mizuno, Tomoya ;
Nakamura, Fumihiko ;
Kambara, Tsunehito ;
Nakanishi, Kimihiro ;
Abe, Hideyuki ;
Yoshida, Ken-Ichiro .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (06) :793-808
[4]   Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy [J].
Golshayan, Ali Reza ;
George, Saby ;
Heng, Daniel Y. ;
Elson, Paul ;
Wood, Laura S. ;
Mekhail, Tarek M. ;
Garcia, Jorge A. ;
Aydin, Hakan ;
Zhou, Ming ;
Bukowski, Ronald M. ;
Rini, Brian I. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) :235-241
[5]   Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment [J].
Gruenwald, Viktor ;
Merseburger, Axel S. .
ONCOTARGETS AND THERAPY, 2012, 5 :111-117
[6]   Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC) [J].
Harshman, Lauren C. ;
Yu, R. James ;
Allen, Genevera I. ;
Srinivas, Sandy ;
Gill, Harcharan S. ;
Chung, Benjamin I. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (03) :379-385
[7]   Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma [J].
Horiguchi, A ;
Oya, M ;
Uchida, A ;
Marumo, K ;
Murai, M .
JOURNAL OF UROLOGY, 2003, 169 (02) :710-713
[8]   Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial [J].
Hutson, Thomas E. ;
Lesovoy, Vladimir ;
Al-Shukri, Salman ;
Stus, Viktor P. ;
Lipatov, Oleg N. ;
Bair, Angel H. ;
Rosbrook, Brad ;
Chen, Connie ;
Kim, Sinil ;
Vogelzang, Nicholas J. .
LANCET ONCOLOGY, 2013, 14 (13) :1287-1294
[9]   Upfront, Randomized, Phase 2 Trial of Sorafenib Versus Sorafenib and Low-Dose Interferon Alfa in Patients With Advanced Renal Cell Carcinoma Clinical and Biomarker Analysis [J].
Jonasch, Eric ;
Corn, Paul ;
Pagliaro, Lance C. ;
Warneke, Carla L. ;
Johnson, Marcella M. ;
Tamboli, Pheroze ;
Ng, Chaan ;
Aparicio, Ana ;
Ashe, Robynne G. ;
Wright, John J. ;
Tannir, Nizar M. .
CANCER, 2010, 116 (01) :57-65
[10]   Histopathology of Surgically Treated Renal Cell Carcinoma: Survival Differences by Subtype and Stage [J].
Keegan, Kirk A. ;
Schupp, Clayton W. ;
Chamie, Karim ;
Hellenthal, Nicholas J. ;
Evans, Christopher P. ;
Koppie, Theresa M. .
JOURNAL OF UROLOGY, 2012, 188 (02) :391-397